Search Results
Your search for Daniel M. Geynisman, MD matches 10 pages
Showing 1 - 10Use of Adjuvant Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma: CheckMate 274
Subsequent systemic therapy with the immune checkpoint inhibitor nivolumab may offer overall survival benefit in patients with muscle-invasive urothelial carcinoma who underwent surgery to remove their tumors, according to recent findings presented by Geynisman et al at the 2024 ASCO Genitourinary...
Single-Arm Phase II Noninferiority Trial Evaluates Active Surveillance vs Cystectomy Following Neoadjuvant Chemotherapy for Muscle-Invasive Urothelial Carcinoma
Researchers have found that following chemotherapy, 46% of patients with muscle-invasive urothelial carcinoma were able to avoid a cystectomy and achieve a 2-year metastasis-free survival, according to new findings presented by Daniel M. Geynisman, MD, and colleagues at the 2023 ASCO Genitourinary...
Expert Point of View: Daniel M. Geynisman, MD
Invited discussant Daniel M. Geynisman, MD, of Fox Chase Cancer Center, Philadelphia, found the longer-term follow-up of KEYNOTE-564 “reassuring.” Dr. Geynisman continued: “Following nephrectomy, the goal of adjuvant treatment is to ideally cure or at least significantly delay disease progression. ...
Expert Point of View: Daniel M. Geynisman, MD
Invited discussant Daniel M. Geynisman, MD, of Fox Chase Cancer Center, Philadelphia, found the longer-term follow-up of KEYNOTE-564 “reassuring.” Dr. Geynisman continued: “Following nephrectomy, the goal of adjuvant treatment is to ideally cure or at least significantly delay disease progression. ...
Expert Point of View: Daniel M. Geynisman, MD
Invited discussant Daniel M. Geynisman, MD, of Fox Chase Cancer Center, Philadelphia, found the longer-term follow-up of KEYNOTE-564 “reassuring.” Dr. Geynisman continued: “Following nephrectomy, the goal of adjuvant treatment is to ideally cure or at least significantly delay disease progression....
No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes
A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they were treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab. These...
Daniel M. Geynisman, MD, on Bladder Cancer: Risk-Enabled Treatment After Neoadjuvant Chemotherapy
Daniel M. Geynisman, MD, of Fox Chase Cancer Center, discusses phase II results from the RETAIN BLADDER study, which sequenced bladder tumor samples while treating patients with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. The goal was to increase metastasis-free...
Doctor, Where Art Thou?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Actively Recruiting Clinical Trials for Muscle-Invasive and Non–Muscle-Invasive Bladder Cancers
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical research trials for both muscle-invasive and non–muscle-invasive bladder cancers. The studies listed here are evaluating the safety and efficacy of combinations of chemotherapy and...
ASCO 2015: African Americans Prone to Display Negative Perceptions of Cancer-Related Clinical Trials
African American patients have a disproportionately high rate of cancer and yet are less likely than Caucasian patients to participate in oncologic clinical trials that can significantly improve quality of life. Researchers from Fox Chase Cancer Center and Temple University explored the differences ...
